Total Payments
$384.54
2023 Payments
$20.25
Companies
6
Transactions
9
Medicare Patients
1,299
Medicare Billing
$61,530
Payment Breakdown by Category
Food & Beverage$363.96 (94.6%)
Education$20.58 (5.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $363.96 | 8 | 94.6% |
| Education | $20.58 | 1 | 5.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $143.66 | 2 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $124.99 | 1 | $0 (2021) |
| Amgen Inc. | $37.79 | 2 | $0 (2023) |
| Genentech USA, Inc. | $31.45 | 2 | $0 (2021) |
| Otsuka America Pharmaceutical, Inc. | $26.07 | 1 | $0 (2021) |
| OPKO Pharmaceuticals, LLC | $20.58 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $20.25 | 1 | Amgen Inc. ($20.25) |
| 2021 | $364.29 | 8 | AstraZeneca Pharmaceuticals LP ($143.66) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/03/2023 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $20.25 | General |
| Category: Cardiology | ||||||
| 12/09/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $16.57 | General |
| Category: Virology & Specialty Care | ||||||
| 10/28/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $14.88 | General |
| Category: Virology & Specialty Care | ||||||
| 10/21/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: RESPIRATORY | ||||||
| 06/29/2021 | Amgen Inc. | Parsabiv (Drug), Sensipar | Food and Beverage | In-kind items and services | $17.54 | General |
| Category: Nephrology | ||||||
| 03/10/2021 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $124.94 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/03/2021 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/26/2021 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Education | In-kind items and services | $20.58 | General |
| Category: NEPHROLOGY | ||||||
| 01/15/2021 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $26.07 | General |
| Category: NEPHROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 422 | 830 | $82,307 | $18,690 |
| 2022 | 17 | 672 | 1,161 | $99,243 | $28,798 |
| 2021 | 4 | 57 | 58 | $11,717 | $4,268 |
| 2020 | 7 | 148 | 161 | $45,434 | $9,774 |
Total Patients
1,299
Total Services
2,210
Medicare Billing
$61,530
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 37 | 37 | $19,710 | $4,288 | 21.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 58 | 63 | $10,954 | $3,011 | 27.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 41 | 42 | $10,786 | $2,958 | 27.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 24 | 26 | $9,251 | $2,068 | 22.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $7,914 | $1,670 | 21.1% |
| 99285 | Emergency department visit with high level of medical decision making | Facility | 2023 | 13 | 13 | $6,851 | $1,447 | 21.1% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 26 | 26 | $3,068 | $900.12 | 29.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 15 | 15 | $3,878 | $744.23 | 19.2% |
| 87400 | Detection test by immunoassay technique for influenza virus | Office | 2023 | 16 | 32 | $1,307 | $443.20 | 33.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 49 | 54 | $3,171 | $361.56 | 11.4% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 19 | 22 | $1,922 | $316.15 | 16.4% |
| 80047 | Blood test, basic group of blood chemicals (calcium, ionized) | Office | 2023 | 12 | 13 | $780.00 | $174.98 | 22.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 13 | 15 | $140.00 | $121.80 | 87.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 13 | 14 | $370.72 | $106.54 | 28.7% |
| 81003 | Automated urinalysis test | Office | 2023 | 16 | 16 | $176.00 | $35.20 | 20.0% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 37 | 366 | $1,588 | $24.98 | 1.6% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 13 | 56 | $439.60 | $19.66 | 4.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 128 | 138 | $23,995 | $8,002 | 33.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 51 | 52 | $13,354 | $4,797 | 35.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 58 | 58 | $14,993 | $4,237 | 28.3% |
| 87637 | Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19), influenza virus types a and b, and respiratory syncytial virus | Office | 2022 | 26 | 26 | $7,764 | $3,653 | 47.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 27 | 27 | $10,684 | $2,947 | 27.6% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2022 | 48 | 48 | $5,664 | $1,664 | 29.4% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 32 | 64 | $5,440 | $1,038 | 19.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 84 | 98 | $5,756 | $851.51 | 14.8% |
About Mariah Thaxton, P.A
Mariah Thaxton, P.A is a Physician Assistant healthcare provider based in Milledgeville, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/08/2010. The National Provider Identifier (NPI) number assigned to this provider is 1174841647.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Mariah Thaxton, P.A has received a total of $384.54 in payments from pharmaceutical and medical device companies, with $20.25 received in 2023. These payments were reported across 9 transactions from 6 companies. The most common payment nature is "Food and Beverage" ($363.96).
As a Medicare-enrolled provider, Thaxton has provided services to 1,299 Medicare beneficiaries, totaling 2,210 services with total Medicare billing of $61,530. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Physician Assistant
- Location Milledgeville, GA
- Active Since 05/08/2010
- Last Updated 05/08/2010
- Taxonomy Code 363A00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1174841647
Products in Payments
- LOKELMA (Drug) $143.66
- OFEV (Drug) $124.99
- Xofluza (Drug) $31.45
- JYNARQUE (Drug) $26.07
- RAYALDEE (Drug) $20.58
- Repatha (Biological) $20.25
- Parsabiv (Drug) $17.54
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.